NAD+: research overview

The short version

NAD+ stands for nicotinamide adenine dinucleotide. It is not a peptide — it is a coenzyme, a small molecule that cells use to carry electrons through energy metabolism and that serves as a consumed substrate for enzymes involved in DNA repair, gene regulation, and inflammation control. It is in every cell of the human body and declines with age.

NAD+ appears here because it shares the same research-enthusiast community as the peptides, because its biology — cellular energy, longevity signaling, metabolic repair — intersects with the same questions. It is a dietary supplement in most regulatory frameworks, not an approved drug, and that difference shapes what we know and don't know about it.

Raising NAD+ levels with precursors (NMN or NR) is well-demonstrated in human trials ^[24][27]. Translation to hard clinical endpoints — longer life, prevention of age-related disease — has not been demonstrated in humans. The most current authoritative synthesis of the human data (2025, Nature Metabolism) concluded that human efficacy data are still limited, and that tissue-specific NAD+ dynamics remain sparse ^[23]. The rodent data are more promising but should not be read as guaranteed to apply in people.

What it is

NAD+ — the oxidized form — is a dinucleotide: two nucleotides (nicotinamide mononucleotide and adenosine monophosphate) joined by two bridging phosphate groups. Molecular formula: C21H27N7O14P2. Its reduced form is NADH. The interconversion between NAD+ and NADH is how cells transfer electrons in energy metabolism.

Important distinctions:

• NAD+ ≠ NMN ≠ NR: Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are precursors — molecules that the body converts into NAD+. Oral NAD+ itself is poorly taken up by cells intact; most researchers and clinicians consider precursors the rational oral route for raising cellular NAD+.
• NAD+ ≠ NADH: The ratio of NAD+ to NADH is what matters metabolically. Supplements promote the oxidized form NAD+ specifically.
• Supplement ≠ drug: NAD+ and NR/NMN are sold as dietary supplements. Injectable compounded NAD+ is a different form with different risk considerations — including a Class I FDA recall of one compounded injectable product for elevated bacterial endotoxin contamination.

How it works

NAD+ operates through two main roles that make it a longevity research target:

1. Central redox carrier (energy metabolism): NAD+ accepts electrons from glucose, fatty acids, and amino acids during glycolysis, the TCA cycle, and oxidative phosphorylation — ultimately enabling ATP synthesis. Without NAD+, cellular energy production stalls.

2. Substrate for NAD-consuming signaling enzymes ^[26]:

• Sirtuins (SIRT1–SIRT7): NAD+-dependent deacylase enzymes that regulate gene expression, stress responses, mitochondrial biogenesis, and DNA repair. Sirtuin activation requires NAD+ as a consumed co-substrate.
• PARPs (chiefly PARP1): Poly(ADP-ribose) polymerases that consume NAD+ in response to DNA damage — a critical repair mechanism but also a potential drain on the NAD+ pool.
• CD38 and CD157: Ectoenzymes that degrade NAD+ and rise with age and inflammation, contributing to age-associated NAD+ decline.
• NAMPT: The rate-limiting enzyme in the NAD+ salvage pathway — the main route by which nicotinamide (from diet and from the sirtuin/PARP reaction) is recycled back to NAD+.

The core hypothesis behind NAD+ supplementation is: tissue NAD+ declines with age (partly because CD38 rises); restoring NAD+ re-activates sirtuins and DNA repair; this slows aspects of cellular aging. The hypothesis is well-supported in animal models. Human translation is the open question ^[26].

What the research shows

Foundational biology review (2021): A comprehensive review in Nature Reviews Molecular Cell Biology established the NAD+ decline-with-age framework, identified the major consuming enzymes (sirtuins, PARPs, CD38), and framed NAD+ restoration as a candidate strategy against age-related metabolic disease. This is the foundational mechanistic reference ^[26].

NMN + insulin sensitivity in humans (2021): In premenopausal postmenopausal women with prediabetes, 10 weeks of oral NMN (250 mg/day) significantly improved skeletal muscle insulin sensitivity (assessed by hyperinsulinemic-euglycemic clamp) and remodeled insulin signaling in muscle tissue. Body composition and HbA1c did not change ^[25].

NR dose-response in humans (2019): In healthy overweight adults, 8 weeks of NR at 100, 300, and 1,000 mg/day dose-dependently raised whole-blood NAD+ by 22%, 51%, and 142% respectively. No flushing, no significant adverse events vs. placebo at any dose; no LDL cholesterol elevation or disruption of one-carbon metabolism ^[27].

NMN multicenter RCT (2023): In middle-aged adults, 60 days of oral NMN at 300–900 mg/day dose-dependently raised blood NAD+ versus placebo (p≤0.001 at days 30 and 60). Walking distance and quality-of-life scores improved; biological age measure did not increase; no safety concerns at any dose. The 600 mg/day dose was identified as potentially optimal ^[24].

2025 Nature Metabolism review: The most current authoritative synthesis concluded that human trials of NAD+ precursors have shown limited efficacy translating to clinical endpoints; that age-related NAD+ decline has been consistently observed only in a limited number of human studies; and that tissue-specific NAD+ dynamics remain sparse. The review calls for more rigorous clinical studies of systemic and tissue-specific NAD+ metabolism rather than reliance on rodent extrapolation ^[23].

Reported effects, cautions & safety

The NAD+ corpus has empty real_world_signals — no structured community-signal data was assembled for this compound in the same way as the peptides — so this section focuses on the documented clinical and safety picture.

Established tolerability in trials: Oral NR and NMN are well-tolerated in controlled trials at the doses studied, with no significant adverse-event differences from placebo in the key dose-response studies ^[24][27]. IV NAD+ administered too quickly can cause chest discomfort, abdominal cramping, flushing, and nausea — effects that are well-known in clinical infusion practice and managed by slowing the infusion rate.

Safety considerations:

Compounded injectable NAD+: The FDA has issued a Class I recall of a compounded NAD+ injection for elevated bacterial endotoxin contamination — a serious manufacturing-quality concern for injectable products outside the pharmaceutical system.

Oral supplement quality: Supplement-grade NMN and NR vary widely in purity and actual content; third-party testing is not guaranteed across the market.

Theoretical cancer consideration: NAD+ supports the metabolism of all rapidly dividing cells, including cancer cells. Raising NAD+ levels theoretically could fuel an existing cancer's metabolism. NAD+ has dual, context-dependent roles in oncology; the signal is not well-characterized clinically. This is a theoretical, not documented, concern.

NMN regulatory uncertainty: The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was investigated as a drug, creating marketplace uncertainty that may affect product availability in the US.

Does NAD+ cause weight gain? No evidence from the trials suggests weight gain as a NAD+ or NMN/NR-specific effect ^[24][27]. This is a commonly asked question that the evidence does not support.

Where it fits

NAD+ is the odd one out on this desk — it is not a peptide, it is not a drug, and it is not unapproved in the way the peptides are. It is a coenzyme that your body already makes and uses constantly, sold in supplement and precursor form.

Its presence here reflects the shared research-community interest: the same people asking about retatrutide and ipamorelin are asking about NAD+ longevity protocols, and the evidence standards and gaps are similar — compelling animal and mechanistic data, promising but limited human trials, and a commercial market that runs well ahead of clinical proof.

The honest assessment: raising blood NAD+ with NMN or NR is achievable and well-tolerated; translating that into meaningful clinical outcomes in aging humans remains unproven as of the most current human-data synthesis ^[23].